These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7413661)

  • 41. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans.
    Cosmi B; Cini M; Legnani C; Pancani C; Calanni F; Coccheri S
    Thromb Res; 2003 Mar; 109(5-6):333-9. PubMed ID: 12818259
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Involvement of cell surface heparin sulfate in the binding of lipoprotein lipase to cultured bovine endothelial cells.
    Shimada K; Gill PJ; Silbert JE; Douglas WH; Fanburg BL
    J Clin Invest; 1981 Oct; 68(4):995-1002. PubMed ID: 6457061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Interaction of aminasin and novocain with acid mucopolysaccharides and mucoproteins].
    Bychkov SM; Khazanova AI
    Vopr Med Khim; 1967; 13(5):491-8. PubMed ID: 4235110
    [No Abstract]   [Full Text] [Related]  

  • 44. Heparin, heparan sulfate, smooth muscle cells, and atherosclerosis.
    Karnovsky MJ; Wright TC; Castellot JJ; Choay J; Lormeau JC; Petitou M
    Ann N Y Acad Sci; 1989; 556():268-81. PubMed ID: 2525359
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of glycosaminoglycans and protamine chloridrate on platelet aggregation induced by collagen and thrombin.
    Luzzatto G; Paolini R; Stevanato F; Simioni P; Cella G
    Angiology; 1989 Mar; 40(3):170-4. PubMed ID: 2916768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition by heparin-modulated antithrombin III of amidolysis catalysed by m beta-acrosin.
    Long WF; Williamson FB
    Biochem J; 1984 Feb; 217(3):721-5. PubMed ID: 6231919
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anticoagulant properties in vitro of heparan sulphates.
    Hubbard AR; Jennings CA; Barrowcliffe TW
    Thromb Res; 1984 Sep; 35(5):567-76. PubMed ID: 6237461
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
    Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
    Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Heparin].
    Roszkowska W; Worowski K
    Postepy Hig Med Dosw; 1984; 38(1):73-124. PubMed ID: 6387687
    [No Abstract]   [Full Text] [Related]  

  • 50. [Acute effects of sulodexide on the lipid profile and on antithrombin III in patients with chronic renal insufficiency in hemodialysis treatment].
    Averna MR; Citarella P; Picone F; Capodicasa G; Galione A; Rini G; Notarbartolo A
    Clin Ter; 1984 Jan; 108(2):111-4. PubMed ID: 6232045
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative effect of heparin and heparan sulphate on two abnormal antithrombin III type 3 variants.
    Fischer AM; Beguin S; Sternberg C; Dautzenberg MD
    Br J Haematol; 1987 Jun; 66(2):213-7. PubMed ID: 2955807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [SOME ANTICOAGULANT PROPERTIES OF THE ARTERIAL WALL].
    DONNER L; HEYROVSKY A
    Thromb Diath Haemorrh; 1964 Jul; 11():476-84. PubMed ID: 14191725
    [No Abstract]   [Full Text] [Related]  

  • 53. Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparan sulphates.
    Casu B; Johnson EA; Mantovani M; Mulloy B; Oreste P; Pescador R; Prino G; Torri G; Zoppetti G
    Arzneimittelforschung; 1983; 33(1):135-42. PubMed ID: 6219676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 55. Effect of heparin and heparin fractions on platelet aggregation.
    Salzman EW; Rosenberg RD; Smith MH; Lindon JN; Favreau L
    J Clin Invest; 1980 Jan; 65(1):64-73. PubMed ID: 6243142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Antithrombin activity and platelet aggregation by acid mucopolysaccharides isolated from Stichopus japonicus Selenka].
    Li JZ; Bao CX; Chen GZ; Zhang GZ; Fan HZ; Chen JD
    Zhongguo Yao Li Xue Bao; 1985 Jun; 6(2):107-10. PubMed ID: 2934941
    [No Abstract]   [Full Text] [Related]  

  • 57. A comparative study on the mechanism of the anticoagulant action of mollusc and mammalian heparins.
    Paiva JF; Santos EA; Jeske W; Fareed J; Nader HB; Dietrich CP
    Comp Biochem Physiol A Physiol; 1995 Jul; 111(3):495-9. PubMed ID: 7614042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of heparin and sulfated polysaccharides on in vitro hepatic phagocytosis.
    Filkins JP; Di Luzio NR
    Proc Soc Exp Biol Med; 1966 Jun; 122(2):548-51. PubMed ID: 4227436
    [No Abstract]   [Full Text] [Related]  

  • 59. The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat.
    Miyake Y; Yokota K; Fujishima Y; Sukamoto T
    Blood Coagul Fibrinolysis; 2001 Jul; 12(5):349-57. PubMed ID: 11505077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Significance of thrombus structure for the antithrombotic effectiveness of thrombocyte aggregation inhibiting substances and anticoagulants].
    Zimmermann R; Lange D; Zeltsch C; Barth P; Mörl H
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1173-4. PubMed ID: 347772
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.